Last reviewed · How we verify

NCT07282496

Evaluation of VEDAN RT-90 Resistant Cassava Starch for Glycemic Control and Prebiotic Fiber Development in a Human Trial

Not yet recruiting NA Last updated 15 December 2025
What this trial tests

NA trial testing RT-90 resistant tapioca starch in Resistant Starch in 115 participants. Not yet recruiting.

Timeline
20 December 2025
Primary endpoint
31 August 2026
31 October 2026

Quick facts

Lead sponsorChung Shan Medical University
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposeprevention
Enrollment115
Start date20 December 2025
Primary completion31 August 2026
Estimated completion31 October 2026
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Chung Shan Medical University

Who can join

Adults 18 to 65, any sex, with Resistant Starch or Tapioca Starch. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the effects of RT-90 resistant cassava starch on glycemic control using a human dietary trial and to evaluate its potential as a prebiotic fiber supplement. This study will assess the efficacy of RT-90 resistant cassava starch in improving glycemic control, body composition, and gut microbiome in healthy individuals.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Chung Shan Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07282496.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing